Biotech | August 09, 2021
Novavax and Serum Institute submits Emergency Use Authorisation of vaccine to regulatory agencies in India, Indonesia and the Philippines
Filing for WHO Emergency Use Authorisation this month
Filing for WHO Emergency Use Authorisation this month
Deal for 100 million doses with additional 100 million through 2023
The first batch will be shipped to the Gamaleya Center for the quality control
PegIFN in COVID19 has several add-on advantages compared to other anti-viral agents
_256_384.jpg)
The company expects to generate an EBITDA margin before special items of around 27 percent in 2021.
EBITDA for the quarter stood at Rs. 427 crore and Net Profit was at Rs. 169 crore. Our Core EBITDA margins stood at 31%.
Subscribe To Our Newsletter & Stay Updated
